Abeona Therapeutics (NASDAQ:ABEO) Receives Overweight Rating from Cantor Fitzgerald

Cantor Fitzgerald reaffirmed their overweight rating on shares of Abeona Therapeutics (NASDAQ:ABEO) in a research note issued to investors on Tuesday, Benzinga reports. Cantor Fitzgerald currently has a $36.00 price target on the biopharmaceutical company’s stock.

Separately, StockNews.com cut shares of Abeona Therapeutics from a hold rating to a sell rating in a research note on Tuesday.

Abeona Therapeutics Stock Down 53.7 %

ABEO stock opened at $3.41 on Tuesday. The firm has a 50 day moving average of $7.49 and a 200 day moving average of $5.65. The stock has a market capitalization of $93.26 million, a PE ratio of -1.32 and a beta of 1.49. Abeona Therapeutics has a 52 week low of $2.83 and a 52 week high of $9.01.

Abeona Therapeutics (NASDAQ:ABEO) last released its earnings results on Monday, March 18th. The biopharmaceutical company reported ($0.64) EPS for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.13). On average, equities research analysts expect that Abeona Therapeutics will post -1.83 earnings per share for the current year.

Institutional Trading of Abeona Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of ABEO. Simplex Trading LLC lifted its stake in Abeona Therapeutics by 1,889.9% during the 3rd quarter. Simplex Trading LLC now owns 14,128 shares of the biopharmaceutical company’s stock valued at $59,000 after acquiring an additional 13,418 shares during the period. Jump Financial LLC acquired a new stake in Abeona Therapeutics during the 4th quarter valued at approximately $199,000. Schonfeld Strategic Advisors LLC acquired a new stake in Abeona Therapeutics during the 3rd quarter valued at approximately $648,000. Worth Venture Partners LLC lifted its stake in Abeona Therapeutics by 76.6% during the 3rd quarter. Worth Venture Partners LLC now owns 281,280 shares of the biopharmaceutical company’s stock valued at $1,184,000 after acquiring an additional 121,969 shares during the period. Finally, Barclays PLC lifted its stake in Abeona Therapeutics by 100.0% during the 3rd quarter. Barclays PLC now owns 371,276 shares of the biopharmaceutical company’s stock valued at $1,564,000 after acquiring an additional 185,638 shares during the period. 80.56% of the stock is currently owned by institutional investors and hedge funds.

About Abeona Therapeutics

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.